Guosen Securities (HK)  
Skip Navigation Links

萧智舜 - 医疗保健
+852 2899 6747

萧智舜在15年十一月份成为国信证券(香港) 经纪有限公司的研究部主管。专注香港业务,他现带领最少七至八人的分析员团队,覆盖约四十多间香港上市公司,函盖四个主要板块。在他从14年起加入国信以来,他亦是覆盖中国医疗保健行业。在此之前,他是中融国际(集团)有限公司一名投资经理, 曾参与香港及国际项目融资推广,包括房地产和综合企业。他曾在销售方担任医疗行业分析员, 子行业包括制药,医疗耗材及器械,中医药,医药推广代理商,医院和其他医疗专科。覆盖客户曾包括香港,中国,台湾,东南亚, 英国,欧洲,和美国。另外,他亦曾在购买方和私募股权研究担任分析工作。在展开其金融事业之前, 他在英国剑桥大学担任博士后研究员, 同时亦得到工业界赞助,用化学科技及合成方法建立新药研发技术。他在英国伦敦大学分别获得化学学士和哲学博士学位, 而他的博士研究专题为合成化学药物用作光动力法治疗癌病肿瘤。

三生制药( 1530 HK) | 买入 | HKD23.2 生物技术与制药
中国中药( 570 HK) | 买入 | HKD6.8 生物技术与制药
金斯瑞生物科技( 1548 HK) | 买入 | HKD36.2 生物技术与制药
雅各臣科研製药( 2633 HK) | 买入 | HKD2.5 生物技术与制药
丽珠集团( 1513 HK) | 买入 | HKD78.6 生物技术与制药
绿叶制药( 2186 HK) | 买入 | HKD11.46 生物技术与制药
四环医药( 460 HK) | 买入 | HKD6.65 生物技术与制药
联邦制药( 3933 HK) | 买入 | HKD11 生物技术与制药
国药控股( 1099 HK) | 买入 | HKD40.2 卫生保健设施/服务
康宁医院( 2120 HK) | 买入 | HKD51.17 卫生保健设施/服务
山东威高( 1066 HK) | 买入 | HKD7 医疗设备

山东威高(1066 HK) | 买入 | HK$7
Shandong Weigao (1066 HK) Eyes on Argon as the new driver - 4月 23, 2018 (9页)  
Shandong Weigao had completed its acquisition of Argon Medical Devices in US on 24 Jan 2018. In 2018, we see Weigao sales from consumables/ orthopaedic and total revenue growth y-o-y at 11%/13%/36%, expecting Argon to turn net profit in 2020 and having Weigao’s EPS CAGR (FY17-20F) at 15.2%. Adding Argon’s valuation, our SOTP-TP rises to HKD7.00 (from HKD6.35). Upgrade to BUY.
Cancer drugs: No import tax but price cut - 4月 17, 2018 (4页)  
On 12 April, the State Council of China cited the details of the executive meeting hosted by Premier Li Keqiang. The limelight was to cut import tax for foreign anti-cancer drugs to zero from 2%-5% in the past, effective 1 May 2018. With all the associated measures such as centralised procurement, we expect these foreign drugs need to sacrifice their selling price for bigger sales volume boost in China, similar to the case in Beijing for Herceptin. However, local anti-cancer drugs would have more pricing advantage than these imported drugs.
国药控股(1099 HK) | 买入 | HK$40.2
Sinopharm (1099 HK) Market leader with no fear of the storm - 4月 12, 2018 (7页)  
On 10 April, Sinopharm issued profit warning with 1Q18 earnings to fall 30% y-o-y, on (1) less drug sales via hospitals to outpatients and controlled medical reimbursement; and (2) more opex to sales/ finance costs for deeper sales coverage. We see Sinopharm as #1 distributor will pick up sales and cost control, having earnings growth by end of each year. Maintain BUY with lower SOTP-TP at HKD40.20.
绿叶制药(2186 HK) | 买入 | HK$11.46
Luye Pharma Group (2186 HK) Jan-Feb 18 on track and R&D on progress - 4月 12, 2018 (6页)  
On 10 April, Luye Pharm announced its LY03003 (Rotigotine Extended Release Microsphers) has been approved from the CFDA to proceed to China’s Phase III clinical trial. From Jan to Feb 2018, based on IQVIA, existing core products sales of Lipusu, Beixi and Xuezhikang at 26%/22%/11% y-o-y growth appear to be broadly on-track with our full-year growth at 17%/29%/15% y-o-y. Maintain BUY with higher TP at HKD11.46 on bigger LY03003’s success rate for R&D valuation.
丽珠集团(1513 HK) | 买入 | HK$78.6
Livzon Pharma (1513 HK) Growth supported by IIaprazole types - 4月 11, 2018 (12页)  
Livzon Pharm, on 25 Mar, released its 2017 net profit at RMB4.4bn (+465% y-o-y) on property disposal gain; core profit rose 20% y-o-y to RMB820m, 7% below ours and Bloomberg estimate. In 2018, we see (1) broadly a 7% y-o-y product price cut; (2) Ilaprazole injection just started sales, accelerating FY18-19 revenue growth to 18%/19% y-o-y. Keep BUY with lower DCF-TP at HKD78.60 on lower sales and margin.


+852 2899 6747


+852 2899 6758


+852 2899 3141


+852 2899 6747

CopyRight © 2009-2015 国信证券(香港)经纪有限公司版权所有